自体非清髓性造血干细胞移植治疗视神经脊髓炎
中位随访57个月,12例无其他活动性自身免疫病的患者中80%停用全部免疫抑制治疗且无复发(p < 0.001),11例基线AQP4-IgG阳性者中9例转阴,转阴者均未复发。
要点
- 12例无其他活动性自身免疫病的NMOSD患者中80%移植后停用免疫抑制且无复发。
- 11例基线AQP4-IgG阳性者中9例转阴,转阴者均未复发。
- 2例持续AQP4-IgG阳性者均在移植后2年内复发。
核心结论
- 非清髓性自体造血干细胞移植后可实现长期无药缓解并伴AQP4-IgG转阴,值得进一步研究。
研究设计与样本
- 预处理方案包括环磷酰胺200 mg/kg分第-5至-2天静脉给药、rATG总量6 mg/kg及利妥昔单抗500 mg第-6和+1天,第0天回输未经选择的外周血干细胞。
主要发现
- 中位随访57个月,12例无其他活动性共存自身免疫病的NMOSD患者中11例移植后超过5年,80%停用全部免疫抑制且无复发(p < 0.001)。
- 移植后5年EDSS评分从基线均值4.4改善至3.3(p < 0.01),NRS评分从基线均值69.5改善至85.7(p < 0.01)。
- SF-36生活质量总分5年时从均值34.2改善至62.1(p = 0.001)。
- 11例基线AQP4-IgG阳性者中9例转阴,7例有移植前后检测者中6例血清补体激活和细胞杀伤能力转为阴性。
- 2例持续AQP4-IgG阳性(伴持续补体激活和细胞杀伤能力)者在移植后2年内复发,转阴者均未复发。
临床怎么用
- 对于AQP4-IgG阳性且无其他活动性自身免疫病的NMOSD患者,自体非清髓性HSCT或可作为挽救治疗选择。
- 移植后AQP4-IgG转阴且补体激活/细胞杀伤能力消失者可能提示持续无药缓解。
局限性
- 1例合并活动性SLE的患者移植后10个月死于狼疮并发症。
- 部分检测方法为当时可用的免疫荧光或细胞结合试验,未统一采用最新方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) could be a salvage therapy for neuromyelitis optica spectrum disorder (NMOSD). METHODS: Thirteen patients were enrolled in a prospective open-label cohort study (11 NMOSD aquaporin-4-immunoglobulin G [AQP4-IgG]-positive, 1 NMOSD without AQP4, and 1 NMOSD AQP4-IgG-positive with neuropsychiatric systemic lupus erythematosus [SLE]). Following stem cell mobilization with cyclophosphamide (2 g/m2) and filgrastim, patients were treated with cyclophosphamide (200 mg/kg) divided as 50 mg/kg IV on day -5 to day -2, rATG (thymoglobulin) given IV at 0.5 mg/kg on day -5, 1 mg/kg on day -4, and 1.5 mg/kg on days -3, -2, and -1 (total dose 6 mg/kg), and rituximab 500 mg IV on days -6 and +1. Unselected peripheral blood stem cells were infused on day 0. AQP4-IgG antibody status was determined by Clinical Laboratory Improvement Amendments-validated ELISA or flow cytometry assays. Cell-killing activity was measured using a flow cytometry-based complement assay. RESULTS: Median follow-up was 57 months. The patient with coexistent SLE died of complications of active lupus 10 months after HSCT. For the 12 patients with NMOSD without other active coexisting autoimmune diseases, 11 patients are more than 5 years post-transplant, and 80% are relapse-free off all immunosuppression (p < 0.001). At 1 and 5 years after HSCT, Expanded Disability Status Scale score improved from a baseline mean of 4.4 to 3.3 (p < 0.01) at 5 years. The Neurologic Rating Scale score improved after HSCT from a baseline mean of 69.5 to 85.7 at 5 years (p < 0.01). The Short Form-36 health survey for quality of life total score improved from mean 34.2 to 62.1 (p = 0.001) at 5 years. In the 11 patients whose baseline AQP4-IgG serostatus was positive, 9 patients became seronegative by the immunofluorescence or cell-binding assays available at the time; complement activating and cell-killing ability of patient serum was switched off in 6 of 7 patients with before and after HSCT testing. Two patients remained AQP4-IgG-seropositive (with persistent complement activating and cell-killing ability) and relapsed within 2 years of HSCT. No patient with seronegative conversion relapsed. CONCLUSION: Prolonged drug-free remission with AQP4-IgG seroconversion to negative following nonmyeloablative autologous HSCT warrants further investigation.
引用
- Burt RK, Balabanov R, Han X, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019. PMID: 31578302. doi:10.1212/WNL.0000000000008394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。